PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: bachelor of science

DO NOT CRUSH MEDICATIONS

DO NOT CRUSH MEDICATIONS at SFGH Active Ingredient Drug Product Dosage Form Reasons/ Comments Acitretin Soriatane Capsule Teratogenj Alendronate Fosamax Tablet Mucous membrane irritant Aspirin EC h Bayer EC, Ecotrin Tablet/ Caplet Enteric coated, non EC tabs available Aspirin/dipyridamole Aggrenox Capsule Slow-release Bisacodyl Dulcolax Tablet Enteric coated c Bupropion SR/XL h Wellbutrin SR, Wellbutrin XL Tablet Slow-release b Cabergoline Dostinex Tablet Reproductive harm, carcinogenj Capecitabine Xeloda Tablet antineoplastic agent i Carbamazepine XR h Tegretol XR Tablet Slow-release, reproductive harm, carcinogen b,j Chloral hydrate Somnote Capsule Liquid filled Chlorambucil Leukeran Tablet antineoplastic agent i Cinacalcet Sensipar Tablet Note: tablets are not scored and cutting may cause variable dosage accuracy Clonazepam Klonopin Tablet Teratogen j Cyclophosphamide Cytoxan Tablet Cytotoxic, change order to IV formulation/ route i Cyclosporine Sandimmune, Neoral, Gengraf Capsule Immunosuppressive b,j Diclofenac Voltaren Tablet Delayed-release Didanosine Videx EC Capsule Delay

NIOSH List of Antineoplastic and Other Hazardous Drugs in Health Care Settings. 4. SFGH Administrative Policy 16.36; Non-Cytotoxic Hazardous Drugs Management, Appendix A. (Updated 9/2013) A. Logan, K Pang, K Slown 10/2013 . Title: DO NOT CRUSH MEDICATIONS Author: amy logan Created Date: 10/29/2013 10:50:11 AM ...

Fullscreen Download

Tags:

  Lists, Antineoplastic

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of DO NOT CRUSH MEDICATIONS

Documents from same domain

DO NOT CRUSH MEDICATIONS

sfghpharmacyrainbow.weebly.com

Propranolol h Inderal LA Capsule Extended-release b Propylthiouracil Propylthiouracil Tablet Teratogen, carcinogen i Pyridostigmine Mestinon ER Tablet Extended-release b Raloxifene Evista Tablet Taste, teratogenic potential g Ribavirin Copegus, Rebetol, Ribasphere Tablet/capsule Reproductive harm b

  Ireland, Crush

Related documents

NIOSH List of Antineoplastic and Other Hazardous Drugs …

www.cdc.gov

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012. This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for

  Drug, Other, Lists, Hazardous, Antineoplastic, List of antineoplastic and other hazardous drugs

NIOSH List of Antineoplastic and Other Hazardous Drugs in ...

www.cdc.gov

NIOSH [2016]. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa-

  Center, Control, Centers for disease control and prevention, Disease, Prevention, Lists, Antineoplastic

USP <800> USP 800> Hazardous Drugs-Handling in …

thecomplianceteam.org

Apr 08, 2021 · NIOSH List Tables 2004-2010-2012-2014-2016 ... antineoplastic agents or are not Active Pharmaceutical Ingredients (API) Assessment of Risk (AOR) •Minimum Considerations –Type of HD –Dosage form –Risk of exposure –Package –Manipulation. Personnel Requirements •Compounding personnel (if applicable)

  Lists, Antineoplastic

Johns Hopkins Health System and Office of Injection and ...

www.hopkinsmedicine.org

Note: The administration of an antineoplastic drug, non-radionuclide anti-neoplastic drug, anti-neoplastic agent or certain monoclonal antibodies is coded as a chemotherapy infusion procedure. See approved list of non-chemotherapeutic drugs in the attached APPENDIX A.

  Lists, Anti, Antineoplastic, Neoplastic, Anti neoplastic

CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS …

mpha.in1touch.org

ACKNOWLEDGEMENT: This list is adapted from the National Institute for Occupational Safety and Health (NIOSH) Health Alert, "Preventing Occupational Exposures to Antineoplastic and other Hazardous Drugs in Healthcare Settings” (September 2004, updated September 2010) for use in WRHA facilities and CancerCare Manitoba.

  Lists, Antineoplastic

DRUG BENEFIT LIST - Canada

www.canada.ca

2. PURPOSE OF THE NIHB DRUG BENEFIT LIST (DBL) The Drug Benefit List (DBL) is a listing of the drugs provided as benefits by the NIHB Program. The DBL is updated regularly and published regularly. The listed drugs are those primarily used in a home or ambulatory setting.

  Lists

Alberta Drug Benefit List - Blue Cross

www.ab.bluecross.ca

The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must

  Drug, Benefits, Lists, Benefit drug list

FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option

www.caremark.com

1 FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option Effective January 1, 2022 The FEP formulary includes the preferred drug list which is comprised of Tier 1, generics and Tier 2, preferred brand-name drugs. Also included in the formulary are Tier 3, non-preferred brand-name drugs, Tier 4, preferred specialty drugs and Tier 5, non-preferred specialty

  Lists, Formulary

Related search queries

List of Antineoplastic and Other Hazardous Drugs, List, Antineoplastic, Centers for Disease Control and Prevention, Anti-neoplastic, Drug Benefit List, Formulary